Table 4. Frequently occurring adverse events.
Placebo | 15 mg pioglitazone | 45 mg pioglitazone | Total | |
---|---|---|---|---|
Oedema | 9 (13%) | 4 (6%) | 13 (19%) | 26 (12%) |
Cardiovascular events | 8 (11%) | 4 (6%) | 6 (9%) | 18 (9%) |
Diarrhoea | 3 (4%) | 7 (10%) | 3 (4%) | 13 (6%) |
Nausea | 3 (4%) | 6 (8%) | 7 (10%) | 16 (8%) |
Raised blood creatine phosphokinase | 11 (15%) | 12 (17%) | 7 (10%) | 30 (14%) |
Dizziness | 6 (8%) | 5 (7%) | 6 (9%) | 17 (8%) |
Fatigue | 3 (4%) | 8 (11%) | 2 (3%) | 13 (6%) |
Data are n (%) of patients.